Follow this preprint
How does the proportion of never treatment influence the success of mass drug administration programmes for the elimination of lymphatic filariasis?
Klodeta Kura, Wilma A. Stolk, Maria-Gloria Basáñez, Benjamin S. Collyer, Sake J. de Vlas, Peter J Diggle, Katherine Gass, Matthew Graham, View ORCID ProfileT. Déirdre Hollingsworth, Jonathan D. King, Alison Krentel, Roy M. Anderson, View ORCID ProfileLuc E. Coffeng
doi: https://doi.org/10.1101/2023.10.20.23297321
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Klodeta Kura
1London Centre for Neglected Tropical Disease Research, London, United Kingdom
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, United Kingdom
3MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
Wilma A. Stolk
4Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Maria-Gloria Basáñez
1London Centre for Neglected Tropical Disease Research, London, United Kingdom
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, United Kingdom
3MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
Benjamin S. Collyer
1London Centre for Neglected Tropical Disease Research, London, United Kingdom
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, United Kingdom
3MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
Sake J. de Vlas
4Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Peter J Diggle
5Centre for Health Informatics, Computing and Statistics, Lancaster University, Lancaster, United Kingdom
Katherine Gass
6Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America
Matthew Graham
7Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom
8Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom
T. Déirdre Hollingsworth
7Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom
Jonathan D. King
9Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland
Alison Krentel
10Bruyère Research Institute, Canada
11School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Canada
Roy M. Anderson
1London Centre for Neglected Tropical Disease Research, London, United Kingdom
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, United Kingdom
3MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
Luc E. Coffeng
4Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Data Availability
All data produced in the present work are contained in the manuscript
Posted October 21, 2023.
How does the proportion of never treatment influence the success of mass drug administration programmes for the elimination of lymphatic filariasis?
Klodeta Kura, Wilma A. Stolk, Maria-Gloria Basáñez, Benjamin S. Collyer, Sake J. de Vlas, Peter J Diggle, Katherine Gass, Matthew Graham, T. Déirdre Hollingsworth, Jonathan D. King, Alison Krentel, Roy M. Anderson, Luc E. Coffeng
medRxiv 2023.10.20.23297321; doi: https://doi.org/10.1101/2023.10.20.23297321
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (415)
- Allergy and Immunology (736)
- Anesthesia (216)
- Cardiovascular Medicine (3154)
- Dermatology (268)
- Emergency Medicine (468)
- Epidemiology (13120)
- Forensic Medicine (15)
- Gastroenterology (876)
- Genetic and Genomic Medicine (4944)
- Geriatric Medicine (456)
- Health Economics (758)
- Health Informatics (3110)
- Health Policy (1110)
- Hematology (415)
- HIV/AIDS (983)
- Medical Education (460)
- Medical Ethics (121)
- Nephrology (508)
- Neurology (4697)
- Nursing (249)
- Nutrition (695)
- Oncology (2422)
- Ophthalmology (689)
- Orthopedics (271)
- Otolaryngology (334)
- Pain Medicine (313)
- Palliative Medicine (88)
- Pathology (523)
- Pediatrics (1258)
- Primary Care Research (530)
- Public and Global Health (7263)
- Radiology and Imaging (1624)
- Respiratory Medicine (950)
- Rheumatology (464)
- Sports Medicine (408)
- Surgery (525)
- Toxicology (66)
- Transplantation (223)
- Urology (193)